NCT05433376Unknown不适用
Clinical Trial of the ShOckwave Coronary Intravascular Lithotripsy (IVL) System Used to Treat CalcIfied Coronary ArtEries (SOLSTICE)
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 20
- 试验地点
- 3
- 主要终点
- Freedom from major adverse cardiac events (MACE) within 30 days of the index procedure.
研究概览
简要总结
This is a small sample size clinical trial in Chinese population to assess the safety and effectiveness of the Shockwave Coronary Intravascular Lithotripsy (IVL) System to treat de novo, calcified, stenotic, coronary lesions prior to stenting.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject ≥18 and ≤80 years of age，male or female.
- •Subjects with native coronary artery disease (including stable or unstable angina and silent ischemia) suitable for PCI
- •Subject or legally authorized representative, signs a written Informed Consent form to participate in the study, prior to any study-mandated procedures
- •Angiographic
- •Evidence of calcification at the lesion site by, a) angiography, with fluoroscopic radio-opacities noted without cardiac motion prior to contrast injection involving both sides of the arterial wall in at least one location and total length of calcium of at least 15 mm and extending partially into the target lesion, OR by b) OCT, with presence of ≥270 degrees of calcium on at least 1 cross section
- •The lesion length must not exceed 40 mm
- •The target vessel reference diameter must be ≥2.5 mm and ≤4.0 mm
- •de novo target lesion stenosis of protected LMCA, or LAD, RCA or LCX (or of their branches), per investigator's assessment with:
- •Stenosis of ≥70% and <100% or
- •Stenosis ≥50% and <70% (visually assessed) that is deemed qualified for PCI by investigator
- •The target vessel must have TIMI flow 3 at baseline (visually assessed; may be assessed after pre-dilatation)
- •Ability to pass a 0.014" guide wire across the lesion
排除标准
- •Any comorbidity or condition which may reduce compliance with this protocol, including follow-up visits
- •Subject experienced an acute MI (STEMI or non-STEMI) within 30 days prior to index procedure
- •Subjects with cardiogenic shock or acute left heart failure; New York Heart Association (NYHA) class III or IV heart failure; left ventricular ejection fraction (LVEF) ≤ 35% within 6 months prior to the procedure (Note: if multiple LVEF assessments were performed, the measurement closest to index procedure will be chosen; it can be assessed in the procedure);
- •History of a stroke or transient ischemic attack (TIA) within 6 months, or any prior intracranial hemorrhage or permanent neurologic deficit
- •Uncontrolled diabetes defined as a HbA1c ≥10%
- •Non-coronary interventional or surgical structural heart procedures (e.g., TAVR, MitraClip, LAA or PFO occlusion, etc.) within 30 days prior to the index procedure
- •Subject refusing or not a candidate for emergency coronary artery bypass grafting (CABG) surgery
- •Uncontrolled severe hypertension (systolic BP >180 mm Hg or diastolic BP >110 mm Hg)
- •Subject is participating in another research study involving an investigational agent (pharmaceutical, biologic, or medical device) that has not reached the primary endpoint
- •Subject is pregnant or nursing (a negative pregnancy test is required for women of child-bearing potential within 7 days prior to enrollment); Or plans to become pregnant within 13 months after the study procedure;
- •Unable to tolerate dual antiplatelet therapy (i.e., aspirin, and either clopidogrel, prasugrel, or ticagrelor) for at least 6 months (for patients not on oral anticoagulation)
- •Subject has an allergy to imaging contrast media which cannot be adequately pre-medicated
- •Renal failure with serum creatinine >2.5 mg/dL or chronic dialysis
- •Active peptic ulcer or upper gastrointestinal (GI) bleeding within 6 months
- •Untreated pre-procedural hemoglobin <10 g/dL or intention to refuse blood transfusions if one should become necessary
- •Coagulopathy, including but not limited to platelet count <100,000 or International Normalized ratio (INR) > 1.7 (INR is only required in subjects who have taken warfarin within 2 weeks of enrollment)
- •Subject has a hypercoagulable disorder such as polycythemia vera, platelet count >750,000 or other disorders
- •Biomarkers [troponin or CK-MB] greater than the upper laboratory normal limit within 72 hours prior to index procedure (note: if both biomarkers are available, both must be normal)
- •Subject has an active systemic infection on the day of the index procedure with either fever, leukocytosis or requiring intravenous antibiotics
- •Subjects with a life expectancy of less than 1 year
- •Planned use of atherectomy, laser or scoring or cutting balloon, or any investigational device other than lithotripsy Angiographic
- •Previous stent within the target vessel implanted within the last year
- •Previous stent within 10 mm of the target lesion regardless of the timing of its implantation
- •Angiographic evidence of a dissection (≥ grade C) in the target vessel at baseline or after guidewire passage
- •Lesions in non-target vessels requiring PCI as below should be excluded:
- •24 hours to 30 days prior to the study procedure if the procedure was unsuccessful or complicated; or
- •In 24 hours prior to the study procedure
- •>30 days after the study procedure
- •Non-target lesion is including left main lesion with diameter stenosis ≥30%
- •Target vessel is too tortuous to deliver a stent assessed by investigators.
- •Definite or possible thrombus (by angiography or intravascular imaging) in the target vessel
- •Evidence of aneurysm in target vessel within 10 mm of the target lesion
- •Target lesion is an ostial location (LAD, LCX, or RCA, within 5 mm of ostium) or an unprotected left main lesion.
- •Target lesion is a bifurcation with ostial diameter stenosis ≥30%
- •Second lesion with >50% stenosis in the same target vessel as the target lesion including its side branches
- •Target lesion is located in a native vessel that can only be reached by going through a saphenous vein or arterial bypass graft
- •Other situations not suitable for enrollment assessed by investigators.
结局指标
主要结局
Freedom from major adverse cardiac events (MACE) within 30 days of the index procedure.
时间窗: 30 days post index procedure
MACE is defined as: * Cardiac death; or * Myocardial Infarction (MI) defined as CK-MB level \> 3 times the upper limit of lab normal (ULN) value with or without new pathologic Q wave at discharge (periprocedural MI) and using the Fourth Universal Definition of Myocardial Infarction beyond discharge (spontaneous MI); or * Target Vessel Revascularization (TVR) defined as revascularization at the target vessel (inclusive of the target lesion) after the completion of the index procedure
Procedural Success
时间窗: in 24 hours post-procedure or prior to discharge, whichever comes first
defined as stent delivery with a residual stenosis \<50% (core laboratory assessed, angiographically) and without in-hospital MACE
次要结局
未报告次要终点
研究者
研究点 (3)
Loading locations...
相似试验
Unknown
不适用
Arsenic Trioxide in Recurrent and Metastatic Ovarian Cancer and Endometrial Cancer With P53 MutationEndometrial CancerOvarian CancerNCT04489706Ruijin Hospital20
进行中（未招募）
1 期
Safety, Tolerability, Pharmacokinetics and Immunogenicity Study of GB002 Recombinant Peptide Inhalation Solution in Healthy SubjectsHealthyNCT06423261Zhejiang Echon Biopharm Limited100
已完成
不适用
A Safety and Efficacy Study of Dissolve™ in Treatment of Coronary Small Vessel DiseaseCoronary Small Vessel DiseaseNCT03376646DK Medical Technology (Suzhou) Co., Ltd.277
Unknown
不适用
SOLUTION Trial in ChinaCalcifications VascularPeripheral Arterial DiseaseNCT05434676Genesis Medtech Corporation20
已完成
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single-dose GZR4DiabetesNCT06548815Gan and Lee Pharmaceuticals, USA43